CoroNAT - Development of monoclonal antibody therapy for COVID-19

In the CoroNAT project, the best antibodies from healthy patients will form the basis for new treatment of the most ill COVID-19 patients. It is now known that some COVID-19 patients produce effective antibodies, while others do not produce quite strong antibodies. In the project, Aarhus University will collect and analyze the naturally formed antibodies from patients who have recovered after being infected with COVID-19. The most effective antibodies will be identified and their binding properties transferred to a development system for recombinant antibodies at Symphogen in Ballerup. These artificial antibodies will be compared to the best natural antibodies. The perspective is large-scale production of artificial and stable antibodies for the treatment of patients, based on the very best natural antibodies from humans. Knowledge of the antibodies may also be used for vaccine development.